CD19 and B-cell chronic lymphocytic leukemia: In a study of advanced, heavily pretreated patients with high-risk chronic lymphocytic leukemia (CLL) who received CD19 CAR-T therapy, biomarker profiles from autologous infusion products after CAR-T stimulation, demonstrated a correlation with the degree of treatment response (17).